MK-677 vs Sermorelin
MK-677 (Ibutamoren) is an oral, non-peptide ghrelin receptor agonist that stimulates growth hormone release. Sermorelin is an injectable GHRH analogue that stimulates GH through the natural releasing hormone pathway. They represent fundamentally different approaches to enhancing the growth hormone axis.
Last updated: 2026-03-13
MK-677 (Ibutamoren) and Sermorelin are both growth hormone secretagogues — compounds that stimulate the body's own production of growth hormone — but they achieve this through entirely different receptor systems and mechanisms. Understanding these differences is essential for appreciating their distinct pharmacological profiles, advantages, and limitations.
MK-677 is a non-peptide, orally active ghrelin/growth hormone secretagogue receptor (GHS-R1a) agonist. Despite often being categorised alongside peptides, it is actually a small molecule (not a peptide), which is why it can be taken orally. It mimics the hunger hormone ghrelin and stimulates GH release through ghrelin receptor activation.
Sermorelin (also known as GRF 1-29) is a synthetic peptide analogue of the first 29 amino acids of natural growth hormone releasing hormone (GHRH). It stimulates GH release through the GHRH receptor on pituitary somatotrophs — the same physiological pathway used by endogenous GHRH.
**Important Note:** Sermorelin has had limited clinical approval (previously FDA-approved as Geref® for diagnostic use and paediatric GH deficiency, though now discontinued as a branded product). MK-677 has been extensively studied in clinical trials but is not approved for any therapeutic indication. Neither is currently licensed by the MHRA for clinical use in the UK.
Quick Comparison Table
| Category | MK-677 | Sermorelin |
|---|---|---|
| Molecular Type | Non-peptide small molecule (spiroindanylpiperidine) | Synthetic peptide (29 amino acids) |
| Receptor Target | Ghrelin receptor (GHS-R1a) | GHRH receptor (GHRHR) |
| Administration | Oral (capsule/tablet) — key advantage | Subcutaneous injection |
| Half-Life | ~4-6 hours (oral); GH/IGF-1 effects persist 24 hours | ~10-20 minutes (very short) |
| GH Release Pattern | Sustained elevation with amplified pulsatility | Acute GH pulse mimicking physiological release |
| Effect on Appetite | Significantly increases appetite (ghrelin mimetic) | Minimal effect on appetite |
| IGF-1 Elevation | Sustained IGF-1 increase (~40-80% above baseline) | Moderate, transient IGF-1 increase |
| Regulatory Status | Investigational — not approved for any indication | Previously FDA-approved (Geref®, now discontinued). Research compound. |
Mechanism of Action Comparison
MK-677
MK-677 — Oral Ghrelin Receptor Agonist:
MK-677 mimics the endogenous hormone ghrelin by binding to the growth hormone secretagogue receptor type 1a (GHS-R1a), expressed in the hypothalamus and anterior pituitary. Key mechanistic features:
- **Ghrelin receptor activation** — stimulates GH release through a pathway distinct from GHRH, acting primarily through hypothalamic GHS-R1a receptors and directly on pituitary somatotrophs - **Amplified GH pulsatility** — increases both the amplitude and frequency of GH pulses rather than producing a single spike - **Sustained IGF-1 elevation** — oral dosing produces 24-hour GH axis stimulation, leading to sustained IGF-1 increases - **Appetite stimulation** — as a ghrelin mimetic, MK-677 significantly increases appetite and food intake, which can be either beneficial (in wasting conditions) or problematic (in obesity) - **Cortisol effects** — may transiently increase cortisol levels, though this effect typically diminishes with continued use - **Effects on sleep** — increases Stage IV (deep) sleep duration and REM sleep quality, potentially through GH-mediated mechanisms - **No tachyphylaxis** — GH-stimulating effects appear to persist with chronic use without significant desensitisation
Sermorelin
Sermorelin — GHRH Receptor Agonist:
Sermorelin (GRF 1-29) directly activates the GHRH receptor (GHRHR), the same receptor targeted by endogenous growth hormone releasing hormone. Key mechanistic features:
- **Physiological GH release** — produces an acute GH pulse that closely mimics the natural pattern of GH secretion triggered by endogenous GHRH - **Pituitary somatotroph stimulation** — directly stimulates GH synthesis and secretion from anterior pituitary somatotrophs through cAMP/PKA signalling - **Preserved negative feedback** — GH release remains subject to normal somatostatin-mediated negative feedback, preventing excessive GH elevation - **No appetite effects** — does not influence ghrelin pathways, so does not increase hunger - **Short-acting** — very short half-life (~10-20 minutes) means effects are transient and pulsatile - **Potential tachyphylaxis** — some studies suggest reduced responsiveness with chronic use due to GHRH receptor desensitisation - **Requires functional pituitary** — effectiveness depends on adequate somatotroph reserve; less effective in individuals with pituitary insufficiency
Clinical Trial Evidence
MK-677 Clinical Studies
Participants: 65
Duration: 2 years
MK-677 (25 mg daily) increased IGF-1 levels to those of young adults. GH secretory mass increased ~45%. No significant changes in body composition at 2 years despite sustained hormonal effects. Fasting glucose increased modestly.
Longest controlled MK-677 study demonstrating sustained GH axis stimulation without tachyphylaxis but raising metabolic concerns
Participants: 8
Duration: 7 days
MK-677 increased duration of Stage IV sleep by ~50% and REM sleep by ~20%. GH pulsatility was enhanced. Sleep quality improvements were consistent across subjects.
Demonstrated MK-677's beneficial effects on sleep architecture
Sermorelin Clinical Studies
Participants: Multiple paediatric cohorts
Duration: 6-12 months
Sermorelin (30 mcg/kg SC daily) increased growth velocity in GH-deficient children. Effects were modest compared to exogenous GH replacement.
Basis for FDA approval of Geref® for paediatric GH deficiency (subsequently discontinued)
Participants: Diagnostic populations
Duration: Acute (single dose)
Sermorelin reliably stimulated GH release when used as a diagnostic agent to assess pituitary GH reserve.
Validated use as a diagnostic tool for GH deficiency
Benefits Comparison
MK-677 Unique Benefits
- Oral administration — no injections required (unique amongst GH secretagogues)
- Sustained 24-hour GH/IGF-1 elevation from once-daily dosing
- No tachyphylaxis — effects maintained with chronic use (demonstrated over 2 years)
- Significant sleep quality improvements (increased deep and REM sleep)
- Potential body composition benefits (increased lean mass, reduced fat mass in some studies)
- Appetite stimulation beneficial in cachexia, wasting conditions, and frailty
- Extensive clinical trial database including long-term studies
Shared Benefits
- Stimulate endogenous GH production rather than introducing exogenous hormone
- Maintain physiological feedback regulation (at least partially)
- Potential improvements in body composition, sleep quality, and recovery
- May support bone density through IGF-1 elevation
- Less suppression of endogenous GH production compared to exogenous GH
Sermorelin Unique Benefits
- More physiological GH release pattern (pulsatile, mimicking natural GHRH)
- No significant appetite stimulation — advantageous for patients concerned about weight gain
- Preserved somatostatin negative feedback — lower risk of excessive GH elevation
- Historically had regulatory approval (Geref®) — validated by FDA review
- Shorter-acting — effects can be more precisely timed (e.g., pre-sleep)
- Better characterised in paediatric populations
- Commonly co-administered with GHRP peptides like Ipamorelin for synergistic effects
Research & Evidence
MK-677 Research
MK-677 has been studied in multiple Phase II clinical trials across diverse populations including healthy elderly adults, obese individuals, GH-deficient patients, and hip fracture patients. The longest study lasted 2 years. Despite consistent GH/IGF-1 elevation, body composition and functional benefits have been inconsistent across trials, leading to questions about whether sustained IGF-1 elevation translates to clinically meaningful outcomes. Metabolic concerns (glucose, insulin) have tempered enthusiasm for long-term use.
Sermorelin Research
Sermorelin's clinical evidence base is smaller and older. The key studies supported its paediatric approval, but the branded product (Geref®) was discontinued for commercial rather than safety/efficacy reasons. Modern research interest in Sermorelin has been driven primarily by anti-ageing and wellness communities rather than pharmaceutical development. Its short half-life and the availability of newer GHRH analogues (e.g., CJC-1295) have limited continued pharmaceutical investment.
Head-to-Head Analysis
No direct comparison trial exists. MK-677 has the advantage of more extensive and more recent clinical trial data. Sermorelin has the advantage of prior regulatory approval, validating its safety and efficacy for specific indications. For GH axis stimulation, MK-677 appears to produce more sustained effects but carries metabolic risks (glucose/insulin changes) that Sermorelin largely avoids.
Protocol Comparison
MK-677 Protocol
MK-677 (Investigational): Clinical trials used 25 mg orally once daily, typically taken at bedtime to coincide with natural nocturnal GH secretion. Some research has explored 10 mg and 50 mg doses. Once-daily dosing is sufficient due to sustained pharmacological activity. Available as capsules/tablets in research settings.
⚠️ Not approved for therapeutic use. These are research protocols.
Sermorelin Protocol
Sermorelin (Research Compound): Previously prescribed at 0.2-0.3 mg (200-300 mcg) subcutaneous injection before bedtime. Administered daily for therapeutic use or intermittently in some protocols. The pre-sleep timing aligns with natural nocturnal GH peaks. Often used alongside a GHRP such as Ipamorelin to enhance GH pulse amplitude.
Geref® has been discontinued. Current use is in research settings only.
Combined Use
Although both stimulate GH, combination use is pharmacologically questionable. They act through different receptors (GHS-R1a vs GHRHR), so theoretical synergy exists. However, combining an oral daily compound (MK-677) with an injectable short-acting peptide (Sermorelin) is practically awkward. More commonly, Sermorelin is combined with GHRP peptides (e.g., Ipamorelin), whilst MK-677 is used as a standalone oral option. No safety data exists for the combination.
Safety Profiles
MK-677 Safety
MK-677 Safety Profile: The most significant concerns relate to metabolic effects. MK-677 consistently increases fasting blood glucose and insulin levels, with some studies showing progression toward insulin resistance with prolonged use. This is a major limitation for elderly and metabolically vulnerable populations. Other effects: increased appetite and potential weight gain, transient water retention and oedema, increased cortisol (transient), and possible joint pain. The 2-year study did not reveal unexpected serious adverse events but confirmed persistent metabolic effects.
Sermorelin Safety
Sermorelin Safety Profile: Generally well tolerated with a safety profile validated through FDA regulatory review. Common side effects: injection site reactions (redness, pain, swelling), facial flushing, headache, and dizziness. Serious adverse events are rare. Sermorelin does not significantly affect glucose metabolism, appetite, or cortisol levels — a major safety advantage over MK-677. The primary limitation is its short half-life requiring daily injections and potential tachyphylaxis with chronic use.
The Verdict: When to Choose Which?
Choose MK-677 When:
- Oral administration is strongly preferred — MK-677's non-injectable format is a major practical advantage
- Sustained 24-hour GH/IGF-1 elevation is desired rather than transient pulses
- Sleep quality improvement is a primary goal — MK-677 has the strongest evidence for sleep enhancement
- Long-term daily use is planned — MK-677 maintains efficacy without tachyphylaxis
- Appetite stimulation is desired (e.g., in wasting or underweight conditions)
- With the understanding that metabolic monitoring (glucose, insulin) is essential
Choose Sermorelin When:
- More physiological, pulsatile GH release is preferred, mimicking natural GHRH signalling
- Metabolic safety is a priority — Sermorelin has minimal effects on glucose and insulin
- Appetite stimulation is undesirable (e.g., patients already overweight)
- Combination with GHRP peptides like Ipamorelin is planned for synergistic GH stimulation
- Shorter-acting effects are desired for more precise timing of GH pulses
- Prior regulatory approval (albeit discontinued) provides additional safety confidence
Consider Combining When:
- No published data supports combining MK-677 and Sermorelin
- Theoretical synergy exists through complementary receptor pathways (GHS-R1a + GHRHR)
- However, Sermorelin + Ipamorelin is a more commonly discussed and pharmacologically rational combination than Sermorelin + MK-677
Frequently Asked Questions
Conclusion
MK-677 and Sermorelin represent two distinct philosophies of growth hormone axis stimulation. MK-677 offers the convenience of oral dosing and sustained GH/IGF-1 elevation but carries meaningful metabolic risks, particularly regarding glucose homeostasis. Sermorelin provides more physiological pulsatile GH release with fewer metabolic side effects but requires daily injections and may lose efficacy over time. The choice between them involves weighing convenience against physiological fidelity, sustained versus pulsatile GH release, and metabolic risk tolerance. Neither is currently approved for therapeutic use, and both should only be considered under appropriate medical supervision.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither MK-677 nor Sermorelin is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.